{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:31:59Z","timestamp":1790883119739,"version":"4.1.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"<jats:p>In this retrospective cohort of 81 patients with mycosis fungoides treated with oral acitretin, overall response rate was 61% (9% complete, 52% partial) and median time to next treatment was around 23\u201324\u2005months in moderate-\/high-dose groups. Adverse events were infrequent and no cases of hypothyroidism were observed. These findings support acitretin as a well-tolerated, accessible systemic retinoid option for patients with mycosis fungoides.<\/jats:p>","DOI":"10.1093\/bjd\/ljag073","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:45:14Z","timestamp":1772887514000},"page":"1167-1170","source":"Crossref","is-referenced-by-count":3,"title":["Dose-stratified analysis of acitretin vs. bexarotene in mycosis fungoides: a retrospective cohort study"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-5613","authenticated-orcid":false,"given":"Victoria","family":"Garfinkel","sequence":"first","affiliation":[{"name":"Department of Dermatology, The University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-8890","authenticated-orcid":false,"given":"Beth A","family":"Childs","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brielle E","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4278-1872","authenticated-orcid":false,"given":"Kiran A","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-3758","authenticated-orcid":false,"given":"Todd A","family":"Aguilera","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-4644","authenticated-orcid":false,"given":"Praveen\u00a0Ramakrishnan","family":"Geethakumari","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, The University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-4791","authenticated-orcid":false,"given":"Heather W","family":"Goff","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026051910573375500_ljag073-B1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf53","article-title":"Emerging epidemiological trends in primary cutaneous lymphomas: a population-based analysis","author":"Lu","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026051910573375500_ljag073-B2","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"2026051910573375500_ljag073-B3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2003.11.058","article-title":"Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma","volume":"51","author":"Querfeld","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2026051910573375500_ljag073-B4","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1111\/jdv.16567","article-title":"Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study","volume":"34","author":"Nikolaou","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026051910573375500_ljag073-B5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"2026051910573375500_ljag073-B6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaad.2012.07.013","article-title":"Acitretin for the treatment of cutaneous T-cell lymphoma","volume":"68","author":"Cheeley","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2026051910573375500_ljag073-B7","doi-asserted-by":"crossref","first-page":"E491","DOI":"10.1002\/ajh.24564","article-title":"A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome","volume":"91","author":"Hanel","year":"2016","journal-title":"Am J Hematol"},{"key":"2026051910573375500_ljag073-B8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/bjd.21772","article-title":"Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin","volume":"187","author":"Roccuzzo","year":"2022","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag073\/67280522\/ljag073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/6\/1167\/67280522\/ljag073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/6\/1167\/67280522\/ljag073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:57:39Z","timestamp":1779202659000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/6\/1167\/8512231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":8,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,9]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag073","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,9]]}}}